Defining the potency of amikacin against Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii derived from Chinese hospitals using CLSI and inhalation-based breakpoints
Joseph L Kuti,1 Qi Wang,2 Hongbin Chen,2 Henan Li,2 Hui Wang,2 David P Nicolau1 1Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA; 2Department of Clinical Laboratory, Peking University People’s Hospital, Beijing, China Objectives: We report the in vi...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2018-05-01
|
| Series: | Infection and Drug Resistance |
| Online Access: | https://www.dovepress.com/defining-the-potency-of-amikacin-against-escherichia-coli-klebsiella-p-peer-reviewed-article-IDR |